Table 3 List of drugs identified as reversing the perturbational gene signature (negative perturbation profiles and therefore recommended) or promoting the perturbational gene signature (positive perturbation profiles and therefore not recommended) between the high- and low-SKP2 ubiquitination signature groups based on the differential gene-expression data in Supplementary File S1. Only drugs with a false-discovery rate < 0.05 were considered. BC cell lines are marked in bold.
Drug | Cell line | p-value | False-discovery rate |
|---|---|---|---|
Drugs with negative perturbation profiles (recommended drugs) | |||
Trichostatin A | MCF7 | 3.5e−45 | 1.3e−41 |
Trichostatin A | PC3 | 8.4e−24 | 1.5e−20 |
Sirolimus | MCF7 | 1.0e−15 | 1.2e−12 |
LY-294002 | MCF7 | 4.7e−13 | 4.2e−10 |
Trichostatin A | HL60 | 1.3e−12 | 9.0e−10 |
Fulvestrant | MCF7 | 1.4e−09 | 8.5e−07 |
Wortmannin | MCF7 | 6.6e−09 | 3.4e−06 |
Tanespimycin | HL60 | 2.1e−08 | 9.5e−06 |
Sirolimus | PC3 | 2.2e−07 | 8.9e−05 |
LY-294002 | PC3 | 4.0e−07 | 1.4e−04 |
Tanespimycin | MCF7 | 8.8e−06 | 2.9e−03 |
Vorinostat | MCF7 | 1.2e−05 | 3.7e−03 |
LY-294002 | HL60 | 1.5e−05 | 4.2e−03 |
Prochlorperazine | MCF7 | 4.7e−05 | 1.2e−02 |
Thioridazine | MCF7 | 1.1e−04 | 2.6e−02 |
Drugs with positive perturbation profiles | |||
Estradiol | MCF7 | 3.1e−06 | 0.011 |
